

Wiesje M Van Der Flier

List of Articles by Year in descending order

Source: [//exaly.com/author-pdf/1804743/publications.pdf](https://exaly.com/author-pdf/1804743/publications.pdf)

Version: 2025-02-01

819

PR articles

41,147

PR citations

1914

96

PR h-index

2485

193

g-index

888

documents

53393

doc citations

1671

107

h-index

54477

citing authors

#	ARTICLE	IF	CITATIONS
1	The need for personalization when sharing results of amyloid imaging for Alzheimer's disease: Insights from a randomized experimental study. Patient Education and Counseling, 2025, 131, 108587.	2.1	1
2	Neuroinflammation in Alzheimer disease. Nature Reviews Immunology, 2025, 25, 321-352.	53.8	242
3	Tract-specific white matter hyperintensities and neuropsychiatric syndromes: a multicentre memory clinic study. Journal of Neurology, Neurosurgery and Psychiatry, 2025, 96, 697-704.	6.3	3
4	Zooming in on brain inflammation in Alzheimer's disease. Brain, 2025, 148, 1-2.	8.4	2
5	Prevalence of Pathogenic Variants and Eligibility Criteria for Genetic Testing in Patients Who Visit a Memory Clinic. Neurology, 2025, 104, .	1.0	4
6	Needs expressed by people with subjective cognitive decline during amyloid PET disclosure consultations: An observational study. Patient Education and Counseling, 2025, 134, 108668.	2.1	1
7	Identifying pathways to the prevention of dementia: the Netherlands consortium of dementia cohorts. BMC Neurology, 2025, 25, .	1.9	2
8	Real-world datasets for the International Registry for Alzheimer's Disease and Other Dementias (InRAD) and other registries: An international consensus. Journal of prevention of Alzheimer's disease, The, 2025, 12, 100096.	2.8	6
9	Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure. Brain Communications, 2025, 7, .	3.6	1
10	SCD's features and AD biomarkers in cognitively unimpaired samples: A meta-analytic approach for nine cohort studies. Alzheimer's and Dementia, 2025, 21, .	0.5	6
11	Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry). Journal of prevention of Alzheimer's disease, The, 2025, 12, 100099.	2.8	0
12	TREM2 risk variants and associated endophenotypes in Alzheimer's disease. Alzheimer's Research and Therapy, 2025, 17, .	6.6	9
13	Exploring interdisciplinary perspectives on the implementation of personalized medicine and patient-orchestrated care in Alzheimer's disease: A qualitative study within the ABOARD research project. Journal of Alzheimer's Disease, 2025, 105, 120-133.	2.6	0
14	Dynamic PET imaging in patients with unilateral carotid occlusion shows lateralized cerebral hypoperfusion, but no amyloid binding. Journal of Alzheimer's Disease, 2025, 105, 519-530.	2.6	0
15	Individualized lesion-symptom mapping using explainable artificial intelligence for the cognitive impact of white matter hyperintensities. NeuroImage: Clinical, 2025, 46, 103790.	3.3	1
16	Survival Differences Between Individuals With Typical and Atypical Phenotypes of Alzheimer Disease. Neurology, 2025, 104, .	1.0	3
17	Drug delivery strategies to cross the blood-brain barrier in Alzheimer's disease: a comprehensive review on three promising strategies. Journal of prevention of Alzheimer's disease, The, 2025, 12, 100204.	2.8	11
18	Diagnostic performance of plasma A β 42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study. Alzheimer's and Dementia, 2025, 21, .	0.5	10

#	ARTICLE	IF	CITATIONS
19	A novel approach to resilience and its links with education and Alzheimer's disease genetics. <i>Alzheimer's and Dementia</i> , 2025, 21, .	0.5	1
20	Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Network Open</i> , 2025, 8, e2519919.	6.6	2
21	CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , 2025, 17, .	6.6	1
22	Modernizing diagnosis of Alzheimer's disease: A review of global trends and Asia-specific perspectives. <i>Alzheimer's and Dementia</i> , 2025, 21, .	0.5	3
23	Small vessel disease burden and functional brain connectivity in mild cognitive impairment. <i>Cerebral Circulation - Cognition and Behavior</i> , 2024, 6, 100192.	1.0	2
24	Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups. <i>Neurology</i> , 2024, 102, .	1.0	26
25	Contributions of amyloid beta and cerebral small vessel disease in clinical decline. <i>Alzheimer's and Dementia</i> , 2024, 20, 1868-1880.	0.5	7
26	Cerebrospinal fluid proteomics in patients with Alzheimer's disease reveals five molecular subtypes with distinct genetic risk profiles. <i>Nature Aging</i> , 2024, 4, 33-47.	14.5	148
27	Interaction Between Arteriosclerosis and Amyloid- β^2 on Cognitive Function. <i>Journal of Alzheimer's Disease</i> , 2024, 97, 953-961.	2.6	6
28	Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis. <i>Translational Psychiatry</i> , 2024, 14, .	5.2	25
29	Fully automated measurement of plasma A β ₄₂ /40 and p τ ₁₈₁ : Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts. <i>Alzheimer's and Dementia</i> , 2024, 20, 2453-2468.	0.5	35
30	Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The SMART-MR Study. <i>Journal of the American Heart Association</i> , 2024, 13, .	4.0	8
31	Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia. <i>Brain</i> , 2024, 147, 3522-3533.	8.4	4
32	Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study. <i>Alzheimer's and Dementia</i> , 2024, 20, 5647-5661.	0.5	25
33	Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia. <i>Neurology</i> , 2024, 103, .	1.0	17
34	Performance evaluation of neural networks and support-vector regression for lesion-symptom mapping in cerebral small vessel disease. <i>Cerebral Circulation - Cognition and Behavior</i> , 2024, 6, 100256.	1.0	0
35	Enhancing cognitive performance prediction by white matter hyperintensity connectivity assessment. <i>Brain</i> , 2024, 147, 4265-4279.	8.4	10
36	The impact of tau-PET in a selected memory clinic cohort: rationale and design of the TAP-TAU study. <i>Alzheimer's Research and Therapy</i> , 2024, 16, .	6.6	4

#	ARTICLE	IF	CITATIONS
37	CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals. <i>Molecular Neurodegeneration</i> , 2024, 19, .	14.1	4
38	Performance of plasma τ 217 and NfL in an unselected memory clinic setting. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2024, 16, .	2.5	9
39	Markers of amyloid- β 2 deposition and burden of enlarged perivascular spaces in patients with cognitive impairment and small vessel disease. <i>Journal of Alzheimer's Disease</i> , 2024, 102, 981-986.	2.6	1
40	Amyloid β positivity is characterized by decline in semantic fluency: An in-depth investigation of verbal fluency trajectories, item-level characteristics and its prognostic value in patients with subjective cognitive decline. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	1
41	Novel microglial markers that are specifically increased in early clinical AD stages. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
42	Passively collected smartphone behaviour as a reliable and feasible measure for global cognition in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
43	Bridging the Gap between Cognition and Everyday Functioning: A linking Study in Amyloid Positive Participants. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
44	Multi-day at-home assessments of speech acoustics in Dutch cognitively normal adults with and without AD pathology. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
45	Long-read sequencing reveals common structural variants as potential drivers of genetic risk for neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
46	Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
47	Unravelling the role of subcortical brain volumes in the conversion to dementia: a multi-cohort analysis. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
48	The prevalence of tau-PET positivity in aging and dementia. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
49	Cognitive and physical activity are related to increased cognitive reserve in a large memory clinic cohort. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
50	Participant recruitment strategies via the Dutch Brain Research Registry: a comparison of effectiveness and efficiency of different strategies for the multi-domain lifestyle intervention trial FINGER-NL. <i>Alzheimer's and Dementia</i> , 2024, 20, .	0.5	0
51	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2023, 24, 638-644.e1.	2.4	22
52	European consensus for the diagnosis of MCI and mild dementia: Preparatory phase. <i>Alzheimer's and Dementia</i> , 2023, 19, 1729-1741.	0.5	25
53	Precision estimates of relative and absolute cerebral blood flow in Alzheimer's disease and cognitively normal individuals. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2023, 43, 369-378.	4.7	4
54	Strategic white matter hyperintensity locations for cognitive impairment: A multicenter lesion-symptom mapping study in 3525 memory clinic patients. <i>Alzheimer's and Dementia</i> , 2023, 19, 2420-2432.	0.5	50

#	ARTICLE	IF	CITATIONS
55	Dementia prevention in memory clinics: recommendations from the European task force for brain health services. <i>Lancet Regional Health - Europe</i> , The, 2023, 26, 100576.	7.0	124
56	C1q is increased in cerebrospinal fluidâ€derived extracellular vesicles in Alzheimer's disease: A multiâ€cohort proteomics and immunoâ€assay validation study. <i>Alzheimer's and Dementia</i> , 2023, 19, 4828-4840.	0.5	36
57	Motivations of patients and their care partners for visiting a memory clinic. A qualitative study. <i>Patient Education and Counseling</i> , 2023, 111, 107693.	2.1	9
58	Tau protein spreads through functionally connected neurons in Alzheimerâ€™s disease: a combined MEG/PET study. <i>Brain</i> , 2023, 146, 4040-4054.	8.4	51
59	Determinants of quality of life in family caregivers in MCI: a comparison with mild dementia. <i>Aging and Mental Health</i> , 2023, 27, 1983-1989.	2.9	2
60	Antibodies Associated With Autoimmune Encephalitis in Patients With Presumed Neurodegenerative Dementia. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2023, 10, .	6.7	21
61	Psychometric characteristics of the Amsterdam instrumental activities of daily living questionnaire in healthy individuals and NIAâ€AA stages of preclinical Alzheimerâ€™s Disease. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
62	Facilitating clinical use of the Amsterdam instrumental activities of daily living questionnaire: Dutch normative data and clinical cutoff values. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
63	What does heritability of Alzheimerâ€™s disease represent?. <i>PLoS ONE</i> , 2023, 18, e0281440.	2.3	40
64	Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimerâ€™s disease. <i>Journal of Neuroinflammation</i> , 2023, 20, .	9.0	31
65	Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A crossâ€platform validation study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2023, 15, .	2.5	4
66	Multiancestry analysis of the HLA locus in Alzheimerâ€™s and Parkinsonâ€™s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	7.5	39
67	Performance of a [18F]Flortaucipir PET Visual Read Method Across the Alzheimer Disease Continuum and in Dementia With Lewy Bodies. <i>Neurology</i> , 2023, 101, .	1.0	17
68	CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer's disease. <i>Nature Communications</i> , 2023, 14, .	13.7	53
69	Head-to-head comparison of relative cerebral blood flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET in subjects with subjective cognitive decline. <i>EJNMMI Research</i> , 2023, 13, .	2.7	2
70	Bloodâ€based biomarkers in Alzheimer's disease: Future directions for implementation. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2023, 15, .	2.5	8
71	Passive logging of smartphone interactions as a feasible and reliable measure to monitor everyday cognition in Alzheimerâ€™s Disease. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	1
72	Dissecting the shared genetic basis of Alzheimerâ€™s disease and hippocampal volumes. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0

#	ARTICLE	IF	CITATIONS
73	ABOARD Cohort; a national initiative to involve citizens in AD research. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
74	Predicting Sojourn Times across Dementia Disease Stages, Institutionalization, and Mortality. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	1
75	Replication of HLA*DRB1*04:04 allele subtype protective effect against Alzheimer's Disease in cognitively healthy centenarians using long-read sequencing. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
76	Identifying Cognitive Resilience Related Genes Among Genetic Risk Loci of Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	2
77	The Amsterdam Approach: optimizing care and research. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	1
78	The association between AD biomarkers and neuropsychiatric symptoms in subjective cognitive decline; the SCIENCE project. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
79	Can escapees of familial AD help identify protective factors? A case report of an extremely resilient PSEN1 carrier. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
80	Data driven criteria for genetic testing result in an efficient selection of patients with genetic dementia in a clinical setting. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
81	Pooling trial data to identify heterogeneity and characteristics of patients most likely to respond to treatment: a causal forest approach. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
82	Study Design of FINGER: a Multidomain Lifestyle Intervention in Dutch Older Adults to Maintain Optimal Cognitive Functioning. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	1
83	Automated FreeSurfer segmentation and visual quality control in 10,000 MRI scans from a large memory clinic cohort. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	1
84	Reduced visual associative learning is linked to Alzheimer's disease pathology. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
85	Facilitating Clinical Use of the Amsterdam Instrumental Activities of Daily Living Questionnaire: Normative Data and Diagnostic Cutoff Values. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
86	The prevalence of young-onset dementia in the Netherlands: a prospective study. <i>Alzheimer's and Dementia</i> , 2023, 19, .	0.5	0
87	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. <i>Lancet Neurology</i> , The, 2022, 21, 66-77.	17.9	771
88	Psychosocial Effects of COVID-19 Measures on (Pre-)Dementia Patients During Second Lockdown. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 931-939.	2.6	11
89	Everyday Functioning in a Community-Based Volunteer Population: Differences Between Participant- and Study Partner-Report. <i>Frontiers in Aging Neuroscience</i> , 2022, 13, .	4.0	7
90	Differential associations between neocortical tau pathology and blood flow with cognitive deficits in early-onset vs late-onset Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1951-1963.	5.5	16

#	ARTICLE	IF	CITATIONS
91	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	17.6	227
92	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. <i>Neurology</i> , 2022, 98, .	1.0	24
93	Gut Microbiota Composition Is Related to AD Pathology. <i>Frontiers in Immunology</i> , 2022, 12, .	4.9	163
94	Neuropsychiatric Symptoms as Predictor of Poor Clinical Outcome in Patients With Vascular Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 813-824.	1.7	3
95	Challenges at the APOE locus: a robust quality control approach for accurate APOE genotyping. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.6	16
96	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. <i>Neurology</i> , 2022, 98, .	1.0	66
97	Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.6	49
98	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. <i>Brain Communications</i> , 2022, 4, .	3.6	17
99	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100141.	1.0	4
100	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100128.	1.0	0
101	A comparison of two approaches for modeling dementia progression in a changing patient context. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	2.2	4
102	Cerebrovascular disease in suspected non-Alzheimer's pathophysiology and cognitive decline over time. <i>European Journal of Neurology</i> , 2022, 29, 1922-1929.	3.5	14
103	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	25.2	2,005
104	Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 229-239.	2.6	11
105	Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.5	60
106	Subjective cognitive decline and self-reported sleep problems: The SCIENCE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.5	10
107	Determining the Minimal Important Change of Everyday Functioning in Dementia. <i>Neurology</i> , 2022, 99, .	1.0	14
108	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	17.6	77

#	ARTICLE	IF	CITATIONS
109	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease. <i>European Radiology</i> , 2022, 32, 7789-7799.	3.6	11
110	Does Loss of Integrity of the Cingulum Bundle Link Amyloid- β^2 Accumulation and Neurodegeneration in Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 39-49.	2.6	3
111	Framework for Clinical Trials in Cerebral Small Vessel Disease (FINESSE). <i>JAMA Neurology</i> , 2022, 79, 1187.	17.6	70
112	Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.6	10
113	Development and design of a diagnostic report to support communication in dementia: Co-creation with patients and care partners. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	2.5	7
114	Cerebral blood flow, amyloid burden, and cognition in cognitively normal individuals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 50, 410-422.	5.5	13
115	Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. <i>Acta Neuropathologica</i> , 2022, 144, 821-842.	9.2	112
116	Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. <i>Nature Medicine</i> , 2022, 28, 2381-2387.	33.0	362
117	CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. <i>Nature Aging</i> , 2022, 2, 1040-1053.	14.5	69
118	Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer's disease. <i>Nature Genetics</i> , 2022, 54, 1786-1794.	25.2	183
119	Differential responsiveness of outcome measures according to biomarker inclusion criteria: implications for trial design. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	0
120	Memory clinic clinicians' preferences and needs for communication with patients: A multinational survey study from EU-FINGERS & LETHE projects. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	0
121	The impact of COVID-19 restrictions after one year on modifiable risk factors related to brain health in older adults in The Netherlands. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	0
122	Teleneuropsychology in the memory clinic setting: evidence for reliability and usability of videoconference-based neuropsychological testing. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	2
123	A longitudinal study on quality of life along the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	0
124	Protective association of HLA-DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequences. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	2
125	Subjective cognitive decline and clinical progression in the memory clinic: The value of longitudinal self- and informant-report in the SCIENCE project. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	0
126	How e-solutions can help to improve the AD diagnostic pathway. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	0

#	ARTICLE	IF	CITATIONS
127	Rare missense variant (R251G) on APOE counterbalances the Alzheimer's disease risk associated with APOE ϵ 4. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	1
128	Precision estimates of Relative and Absolute Cerebral Blood Flow in Alzheimer's disease and Cognitively Normal individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	0
129	Optimizing cCOG, a web-based tool, to detect dementia with Lewy Bodies.. <i>Alzheimer's and Dementia</i> , 2022, 18, .	0.5	1
130	Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer's disease and healthy controls: A test-retest study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 569-578.	4.7	11
131	Hypertensive Exposure Markers by MRI in Relation to Cerebral Small Vessel Disease and Cognitive Impairment. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 176-185.	6.2	34
132	Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, .	4.8	12
133	Risk of dementia in APOE ϵ 4 carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, .	2.5	22
134	Cross-cohort generalizability of deep and conventional machine learning for MRI-based diagnosis and prediction of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2021, 31, 102712.	3.3	73
135	Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 604-613.	2.2	13
136	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 30, 102660.	3.3	24
137	Biomarker testing in MCI patientsâ€”deciding who to test. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	7
138	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	29
139	Amyloid β 2, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	3.8	14
140	Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [18F]Flortaucipir and [18F]Florbetapir Brain PET Studies. <i>Molecular Imaging and Biology</i> , 2021, 23, 550-559.	2.2	2
141	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	36
142	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1195-1201.	2.6	18
143	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , 2021, 2, e87-e95.	10.3	163
144	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2157-2168.	5.5	29

#	ARTICLE	IF	CITATIONS
145	Alzheimer's disease. <i>Lancet, The</i> , 2021, 397, 1577-1590.	62.3	4,252
146	Contribution of Gut Microbiota to Immunological Changes in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2021, 12, .	4.9	44
147	Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity. <i>Neurology</i> , 2021, 96, .	1.0	71
148	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 381-390.	2.6	16
149	Highly specific and ultrasensitive plasma test detects Aβ ₄₂ and Aβ ₄₀ in Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, .	3.4	69
150	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, .	13.7	272
151	Diagnostic Value of the CSF Aβ-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. <i>Neurology</i> , 2021, 97, .	1.0	90
152	Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	33
153	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods. <i>Neurology</i> , 2021, 97, 474-488.	1.0	78
154	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , 2021, 269, 1375-1385.	3.4	45
155	[¹⁸ F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, .	1.0	23
156	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 269-279.	2.6	22
157	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum. <i>Neurology</i> , 2021, 97, .	1.0	99
158	Sex and Cardiovascular Function in Relation to Vascular Brain Injury in Patients with Cognitive Complaints. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 261-271.	2.6	7
159	Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 741-751.	2.6	6
160	Global Prevalence of Young-Onset Dementia. <i>JAMA Neurology</i> , 2021, 78, 1080.	17.6	319
161	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1367-1377.	2.6	4
162	Genome-wide association study of frontotemporal dementia identifies a C9ORF72 haplotype with a median of 12-G4C2 repeats that predisposes to pathological repeat expansions. <i>Translational Psychiatry</i> , 2021, 11, .	5.2	18

#	ARTICLE	IF	CITATIONS
163	Serum and cerebrospinal fluid Neutrophil gelatinase-associated lipocalin (NGAL) levels as biomarkers for the conversion from mild cognitive impairment to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 107, 1-10.	3.4	19
164	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , 2021, 108, 146-154.	3.4	10
165	Comparing CSF amyloid β biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, .	2.5	47
166	Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, .	4.8	27
167	Differential trajectories of hypometabolism across cognitively-defined Alzheimer TM s disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 31, 102725.	3.3	16
168	The Cognitive Online Self TM Test Amsterdam (COST TM): Establishing norm scores in a community TM dwelling population. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, .	2.5	7
169	Polygenic Risk Score of Longevity Predicts Longer Survival Across an Age Continuum. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 750-759.	3.5	34
170	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services TM part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	89
171	Dementia risk communication. A user manual for Brain Health Services TM part 3 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	45
172	Short Digital Spatial Memory Test Detects Impairment in Alzheimer TM s Disease and Mild Cognitive Impairment. <i>Brain Sciences</i> , 2021, 11, 1350.	2.5	11
173	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services TM part 1 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	44
174	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services TM part 4 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	72
175	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , 2021, 13, .	6.6	158
176	Psychosocial effects of Corona virus measures on (pre TM)dementia patients during 2nd lockdown. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0
177	Can we improve clinical trial design in Alzheimer TM s disease? The participants point of view. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0
178	Neuropsychiatric symptoms in patients with possible vascular cognitive impairment: Does sex matter?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0
179	At TM home assessment of cognitive performance: Establishing norm scores for the Cognitive Online Self TM Test Amsterdam (COST TM). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	1
180	A stepwise approach towards diagnostic workup in dementia using online cognitive tools. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0

#	ARTICLE	IF	CITATIONS
181	Everyday functioning in a community-based volunteer population: Factors associated with concordance between participant and study partner—Report. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0
182	The (non)sense of diagnostic computer tools in memory clinics: An international survey assessing the views of clinicians, patients and caregivers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	1
183	Identifying and characterizing patterns of functional decline in memory clinic patients. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0
184	Subjective cognitive decline and self-reported sleep at a memory clinic: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0
185	The incidence of young onset dementia: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	3
186	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0
187	The Effect of Alzheimer's Disease-Associated Genetic Variants on Longevity. <i>Frontiers in Genetics</i> , 2021, 12, .	2.3	11
188	Study design of FINGER—A multidomain lifestyle intervention in Dutch older adults to prevent cognitive decline. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	4
189	Young-onset dementia in memory clinics in the Netherlands: PRECODE—GP. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.5	0
190	Test-retest repeatability of [¹⁸ F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2464-2474.	4.7	31
191	Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population". <i>Annals of Neurology</i> , 2020, 87, 155-155.	6.6	3
192	Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project. <i>Health Expectations</i> , 2020, 23, 52-62.	2.9	30
193	Determinants of Cross-Sectional and Longitudinal Health-Related Quality of Life in Memory Clinic Patients Without Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 256-264.	2.6	6
194	Methylphenidate and galantamine in patients with vascular cognitive impairment—the proof-of-principle study STREAM-VCI. <i>Alzheimer's Research and Therapy</i> , 2020, 12, .	6.6	21
195	Hippocampal [¹⁸ F]flortaucipir BPND corrected for possible spill-in of the choroid plexus retains strong clinico-pathological relationships. <i>NeuroImage: Clinical</i> , 2020, 25, 102113.	3.3	6
196	Why Is Amyloid- β PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 559-569.	2.6	16
197	Brain amyloid β , cerebral small vessel disease, and cognition. <i>Neurology</i> , 2020, 95, .	1.0	36
198	Immune response and endocytosis pathways are associated with the resilience against Alzheimer's disease. <i>Translational Psychiatry</i> , 2020, 10, .	5.2	55

#	ARTICLE	IF	CITATIONS
199	Profound regional spectral, connectivity, and network changes reflect visual deficits in posterior cortical atrophy: an EEG study. <i>Neurobiology of Aging</i> , 2020, 96, 1-11.	3.4	7
200	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimer's Research and Therapy</i> , 2020, 12, .	6.6	28
201	Identifying a task-invariant cognitive reserve network using task potency. <i>NeuroImage</i> , 2020, 210, 116593.	4.4	17
202	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, .	1.0	87
203	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. <i>Neurology</i> , 2020, 95, .	1.0	32
204	The influence of diversity on the measurement of functional impairment: An international validation of the Amsterdam IADL Questionnaire in eight countries. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, .	2.5	23
205	Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline. <i>Frontiers in Psychiatry</i> , 2020, 11, .	2.4	60
206	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, .	2.5	9
207	Prediction of poor clinical outcome in vascular cognitive impairment: TRACE-VCI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, .	2.5	5
208	cCOG: A web-based cognitive test tool for detecting neurodegenerative disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, .	2.5	15
209	Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, .	4.8	22
210	Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE ϵ 4 genotype. <i>Neurology</i> , 2020, 95, .	1.0	75
211	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. <i>Biomolecules</i> , 2020, 10, 1177.	4.2	20
212	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, .	2.5	13
213	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. <i>Brain</i> , 2020, 143, 2831-2843.	8.4	140
214	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. <i>NeuroImage: Clinical</i> , 2020, 28, 102504.	3.3	17
215	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	0
216	Determinants of cognitive decline and dementia in stage 2: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	0

#	ARTICLE	IF	CITATIONS
217	Functional interpretation of genetic risk loci for dementia using a protein quantitative trait loci (pQTLs) approach in cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	0
218	Tau pathology, relative cerebral flow and cognition in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	3
219	Single-cell profiling of circulating and brain-resident immune cells in a mouse model for amyloidosis and in aged mice. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	0
220	Amyloid β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	1
221	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	0
222	Dutch Brain Research Registry for online study participant recruitment: Design and first results. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	0
223	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	1
224	The evolution of neuropsychiatric symptoms in atypical variants of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	2
225	A mixed-methods approach to establish clinically meaningful categories of impairment in instrumental activities of daily living. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	2
226	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	1
227	Study partner- and self-reported difficulties in cognitively complex everyday activities in participants without objective cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	1
228	Attitudes towards genetic susceptibility testing for Alzheimer's disease dementia in cognitively normal adults: A survey study. <i>Alzheimer's and Dementia</i> , 2020, 16, .	0.5	3
229	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, .	6.6	39
230	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ϵ 4 carriers. <i>Scientific Reports</i> , 2020, 10, .	3.4	28
231	Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3165-3175.	5.5	44
232	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. <i>Antioxidants</i> , 2020, 9, 456.	5.8	25
233	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, .	1.0	171
234	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <i>Molecular Neurodegeneration</i> , 2020, 15, .	14.1	73

#	ARTICLE	IF	CITATIONS
235	A Suboptimal Diet Is Associated with Poorer Cognition: The NUDAD Project. <i>Nutrients</i> , 2020, 12, 703.	4.5	26
236	PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment. <i>Acta Neuropathologica</i> , 2020, 139, 1025-1044.	9.2	62
237	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1061-1070.	2.6	24
238	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1436-1438.	2.4	2
239	The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 735-744.	1.7	63
240	Non-memory cognitive symptom development in Alzheimer's disease. <i>European Journal of Neurology</i> , 2020, 27, 995-1002.	3.5	10
241	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	2.6	36
242	The characterisation of subjective cognitive decline. <i>Lancet Neurology</i> , The, 2020, 19, 271-278.	17.9	1,105
243	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCe project. <i>Neurobiology of Aging</i> , 2020, 89, 99-107.	3.4	46
244	Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project. <i>PLoS ONE</i> , 2020, 15, e0227282.	2.3	31
245	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , 2020, 15, e0226784.	2.3	14
246	Regional [18F]florbetapir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2866-2878.	5.5	38
247	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2020, 12, .	6.6	31
248	Dietary patterns are related to cognitive functioning in elderly enriched with individuals at increased risk for Alzheimer's disease. <i>European Journal of Nutrition</i> , 2020, 60, 849-860.	3.4	43
249	Classification of negative and positive 18F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 48, 721-728.	5.5	21
250	Grey zone amyloid burden affects memory function: the SCIENCe project. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 48, 747-756.	5.5	5
251	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. <i>Movement Disorders</i> , 2020, 35, 859-867.	4.6	62
252	What patients want to know, and what we actually tell them: The ABIDE project. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, .	4.8	14

#	ARTICLE	IF	CITATIONS
253	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1513.e1-1513.e17.	2.4	19
254	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 71-80.	3.4	21
255	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. <i>Brain Communications</i> , 2020, 2, .	3.6	16
256	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, .	6.6	202
257	Amyloid- β^2 misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2020, 12, .	6.6	52
258	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, .	2.5	10
259	An Operational Definition of "Abnormal Cognition" to Optimize the Prediction of Progression to Dementia: What Are Optimal Cut-Off Points for Univariate and Multivariate Normative Comparisons?. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1693-1703.	2.6	5
260	Gray matter atrophy but not vascular brain injury is related to cognitive impairment in patients with heart failure. <i>European Heart Journal</i> , 2020, 41, .	2.2	1
261	Survival in memory clinic cohort is short, even in young-onset dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 726-728.	6.3	38
262	Quantification of [¹⁸ F]florbetapir: A test-retest tracer kinetic modelling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 2172-2180.	4.7	27
263	The Impact of Frailty and Comorbidity on Institutionalization and Mortality in Persons With Dementia: A Prospective Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 165-170.e2.	2.4	29
264	Energy and Protein Intake of Alzheimer's Disease Patients Compared to Cognitively Normal Controls: Systematic Review. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 14-21.	2.4	21
265	Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 317-325.	2.6	27
266	Added value of amyloid PET in individualized risk predictions for MCI patients. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 529-537.	2.5	14
267	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019, 84, 225-234.	3.4	68
268	Clinician-patient communication during the diagnostic workup: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 520-528.	2.5	30
269	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , 2019, 497, 204-211.	1.5	17
270	Prognostic value of Alzheimer's disease biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	3.4	12

#	ARTICLE	IF	CITATIONS
271	Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer's disease spectrum. <i>Alzheimer's Research and Therapy</i> , 2019, 11, .	6.6	45
272	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, .	1.0	64
273	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4674.	4.4	34
274	Amyloid- β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2019, 11, .	6.6	41
275	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. <i>Metabolites</i> , 2019, 9, 236.	3.4	18
276	Frequent Cognitive Impairment in Patients With Disorders Along the Heart-Brain Axis. <i>Stroke</i> , 2019, 50, 3369-3375.	6.0	40
277	ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics. <i>Alzheimer's Research and Therapy</i> , 2019, 11, .	6.6	26
278	Discordant amyloid- β PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, .	6.6	51
279	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	17.9	110
280	Amyloid- β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCE Project. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, .	4.0	51
281	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , 2019, 11, 1161.	4.5	35
282	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	9.2	112
283	Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 389-397.	2.6	39
284	Gray matter T1 ρ /T2 ρ ratios are higher in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 3900-3909.	3.5	51
285	A β 34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , 2019, 10, .	13.7	60
286	High amyloid burden is associated with fewer specific words during spontaneous speech in individuals with subjective cognitive decline. <i>Neuropsychologia</i> , 2019, 131, 184-192.	1.7	38
287	Dietary Patterns Are Related to Clinical Characteristics in Memory Clinic Patients with Subjective Cognitive Decline: The SCIENCE Project. <i>Nutrients</i> , 2019, 11, 1057.	4.5	14
288	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, .	6.6	36

#	ARTICLE	IF	CITATIONS
289	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, .	6.6	28
290	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1273-1286.	2.6	6
291	ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF A β 42, levels in non-demented elderly. <i>Neurobiology of Aging</i> , 2019, 79, 101-109.	3.4	15
292	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101786.	3.3	34
293	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. <i>Neurology</i> , 2019, 92, .	1.0	33
294	Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCE project. <i>Neurobiology of Aging</i> , 2019, 79, 50-58.	3.4	56
295	Automatically computed rating scales from MRI for patients with cognitive disorders. <i>European Radiology</i> , 2019, 29, 4937-4947.	3.6	33
296	Detecting frontotemporal dementia syndromes using MRI biomarkers. <i>NeuroImage: Clinical</i> , 2019, 22, 101711.	3.3	60
297	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 311-322.	2.6	20
298	ICP184: LONGITUDINAL DYNAMIC [¹⁸ F]FLORTAUCIPIR PET REVEALS INCREASED EARLY STAGE TAU PATHOLOGY IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
299	ICP187: [¹⁸ F]FLORTAUCIPIR BINDING STRONGLY CORRELATES TO COGNITION ACROSS THE CLINICAL ALZHEIMER'S DISEASE CONTINUUM, INDEPENDENTLY OF CSF TAU. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
300	F10401: FREQUENCY OF SUBJECTIVE COGNITIVE DECLINE CRITERIA IN STAGE 2 OF THE NEW NIA-AA FRAMEWORK: A MULTICOHORT STUDY FROM THE SUBJECTIVE COGNITIVE DECLINE PROFESSIONAL INTEREST AREA. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
301	F10501: LAB-RELATED PREANALYTICAL FACTORS INFLUENCING PLASMA AMYLOID BETA CONCENTRATIONS. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
302	6071 Extent of hypertensive exposure in relation to vascular brain injury and cognitive impairment using heart-brain magnetic resonance imaging; The Heart-Brain Connection Study. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
303	ICP100: A LONGITUDINAL STUDY OF THE EFFECTS OF EDUCATION AND INTRACRANIAL VOLUME ON COGNITIVE CHANGES AND MORTALITY RATES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
304	F20101: NEURODEVELOPMENTAL DIFFERENCES AND ENVIRONMENTAL INSULTS INVERSELY CORRELATE WITH AGE OF ONSET IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
305	ICP025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
306	TD025: DEVELOPMENT AND USABILITY OF ADAPPT: AN ONLINE TOOL TO SUPPORT CLINICIANS, PATIENTS AND CAREGIVERS IN THE DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0

#	ARTICLE	IF	CITATIONS
307	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. <i>Scientific Reports</i> , 2019, 9, .	3.4	52
308	ICâ€02â€01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
309	ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
310	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i>. <i>Alzheimer's and Dementia</i> , 2019, 15, .	0.5	0
311	High occurrence of transportation and logistics occupations among vascular dementia patients: an observational study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, .	6.6	8
312	PET and CSF amyloid- β^2 status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, .	6.6	27
313	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 1-9.	2.5	19
314	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimerâ€™s disease risk. <i>Nature Genetics</i> , 2019, 51, 404-413.	25.2	2,202
315	Dataâ€driven approaches for tauâ€PET imaging biomarkers in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 638-651.	3.5	37
316	Repeat length variations in ATXN1 and AR modify disease expression in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 73, 230.e9-230.e17.	3.4	7
317	Olfactory and gustatory functioning and food preferences of patients with Alzheimerâ€™s disease and mild cognitive impairment compared to controls: the NUDAD project. <i>Journal of Neurology</i> , 2019, 267, 144-152.	3.4	32
318	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesionâ€symptom mapping study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, E1-E10.	2.1	15
319	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 309-320.	2.6	41
320	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. <i>Neurology</i> , 2018, 90, .	1.0	113
321	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , 2018, 64, 927-937.	1.1	45
322	Time Trend in Persistent Cognitive Decline: Results From the Longitudinal Aging Study Amsterdam. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2018, 73, S57-S64.	2.8	23
323	Long-Term Prognostic Implications ofÂ€Previous Silent Myocardial Infarction inÂ€Patients Presenting With AcuteÂ€Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1773-1781.	6.2	48
324	Single Subject Classification of Alzheimerâ€™s Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1827-1839.	2.6	41

#	ARTICLE	IF	CITATIONS
325	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , 2018, 39, 3143-3151.	3.5	46
326	Vascular cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2018, 4, .	47.2	536
327	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 463-472.	1.2	51
328	Microbleeds are associated with depressive symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 112-120.	2.5	9
329	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, .	6.6	28
330	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018, 61, 238-244.	3.4	35
331	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 75-81.	3.4	64
332	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 61, 198-206.	3.4	49
333	Association of Cerebral Amyloid- β^2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	12.4	146
334	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- β^2 1 β^2 42 Analysis Results. <i>Clinical Chemistry</i> , 2018, 64, 576-585.	1.1	169
335	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. <i>Neurology</i> , 2018, 90, .	1.0	126
336	P3 β^2 403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
337	O1 β^2 10 β^2 06: CONTACTIN β^2 1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
338	O1 β^2 14 β^2 04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESION β^2 SYMPTOM MAPPING STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
339	IC β^2 111: [¹⁸ F]FLORBETAPIR β^2 SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
340	IC β^2 222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
341	P2 β^2 645: IMPAIRED OLFACTORY AND GUSTATORY FUNCTIONING IN PATIENTS WITH ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT: THE NUDAD PROJECT. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	1
342	P2 β^2 350: DETECTING FRONTOTEMPORAL DEMENTIA USING A NOVEL MRI IMAGING BIOMARKER: THE ANTERIOR VERSUS POSTERIOR INDEX. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0

#	ARTICLE	IF	CITATIONS
343	O2â€06â€03: AMYLOIDâ€² LOAD IS RELATED TO WORRIES IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2018, 14, .	0.5	0
344	P2â€248: CONTACTINâ€2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, .	0.5	0
345	ICâ€06â€05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNELUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, .	0.5	0
346	P2â€228: PREâ€ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA. Alzheimer's and Dementia, 2018, 14, .	0.5	0
347	ICâ€Pâ€092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, .	0.5	1
348	P3â€134: CIRCULATING METABOLITES ARE ASSOCIATED WITH WHITE MATTER HYPERINTENSITIES. Alzheimer's and Dementia, 2018, 14, .	0.5	0
349	P4â€106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD. Alzheimer's and Dementia, 2018, 14, .	0.5	1
350	P3â€438: PARAMETRIC IMAGING OF [¹⁸ F]FLORBETAPIR: A TESTâ€RETEST STUDY IN HEALTHY SUBJECTS AND PATIENTS WITH ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, .	0.5	0
351	P3â€289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EUROâ€SCD STUDY. Alzheimer's and Dementia, 2018, 14, .	0.5	0
352	O2â€09â€03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NONâ€ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2018, 14, .	0.5	0
353	P2â€349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. Alzheimer's and Dementia, 2018, 14, .	0.5	0
354	P2â€352: COMMUNICATING UNCERTAINTY WHEN DISCLOSING DIAGNOSTIC TEST RESULT: THE ABIDEâ€CLINICAL ENCOUNTER STUDY. Alzheimer's and Dementia, 2018, 14, .	0.5	0
355	P2â€363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. Alzheimer's and Dementia, 2018, 14, .	0.5	0
356	P2â€134: THE ADDED VALUE OF EXTREME PHENOTYPES IN ALZHEIMER'S DISEASE CASEâ€CONTROL STUDIES. Alzheimer's and Dementia, 2018, 14, .	0.5	0
357	P2â€360: [¹⁸ F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, .	0.5	0
358	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. Alzheimer's and Dementia, 2018, 14, .	0.5	0
359	O2â€03â€03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, .	0.5	0
360	P4â€038: IS <i>SORL1</i> AN AUTOSOMAL DOMINANT ALZHEIMER GENE?. Alzheimer's and Dementia, 2018, 14, .	0.5	1

#	ARTICLE	IF	CITATIONS
361	P2â€500: PHYSICAL PERFORMANCE IN RELATION TO COGNITIVE FUNCTIONING IN PATIENTS WITH DISORDERS ALONG THE HEARTâ€BRAIN AXIS. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
362	O2â€06â€01: [¹⁸ F]FLORBETAPIR SPECIFIC BINDING IN RELATION TO COGNITION IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
363	O5â€04â€01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
364	ICâ€Pâ€093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
365	ICâ€Pâ€033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
366	P3â€342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
367	ICâ€Pâ€032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
368	ICâ€Pâ€192: DISEASEâ€STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	2
369	F5â€05â€04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
370	O3â€13â€06: TAKING AMYLOID PET INTO THE CLINIC: INDIVIDUALIZED RISK PREDICTION IN MCI PATIENTS â€” THE ABIDE PROJECT. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
371	O3â€14â€03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
372	O5â€01â€03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€NEGATIVE MATRIX FACTORIZATION. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
373	P2â€284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
374	Diagnostiek van dementie: praktijkvariatie in Nederlandse geheugenpoliklinieken. <i>Neuropraxis</i> , 2018, 22, 137-146.	0.0	3
375	P3â€617: NUTRITIONAL INTAKE IN SUBJECTIVE COGNITIVE DECLINE: ROOM FOR IMPROVEMENT?. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
376	Diagnostiek van de ziekte van Alzheimer. <i>Neuropraxis</i> , 2018, 22, 172-179.	0.0	0
377	F4â€08â€01: PLASMA AMYLOID AS A PREâ€SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2018, 14, .	0.5	0
378	Î±â€Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , 2018, 33, 1724-1733.	4.6	97

#	ARTICLE	IF	CITATIONS
379	Computer-assisted prediction of clinical progression in the earliest stages of AD. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 726-736.	2.5	12
380	Angiotensin-like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. Brain, 2018, 141, 3377-3388.	8.4	41
381	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, .	4.0	33
382	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 563-572.	2.5	74
383	Prevalence of amyloid β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	6.6	186
384	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. Frontiers in Aging Neuroscience, 2018, 10, .	4.0	93
385	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. Brain, 2018, 141, 3443-3456.	8.4	140
386	ICP-187: CORTICAL T1 ρ /T2 ρ RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, .	0.5	0
387	Clinical phenotype, atrophy, and small vessel disease in <i>APOE</i> ϵ ₂ carriers with Alzheimer disease. Neurology, 2018, 91, .	1.0	54
388	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Annals of Neurology, 2018, 84, 648-658.	6.6	291
389	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 625-632.	3.3	29
390	Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 631-642.	2.6	29
391	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. Alzheimer's Research and Therapy, 2018, 10, .	6.6	54
392	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Alzheimer's Research and Therapy, 2018, 10, .	6.6	26
393	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. Annals of Clinical and Translational Neurology, 2018, 5, 1037-1047.	3.8	31
394	Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer's Disease, 2018, 62, 1091-1111.	2.6	317
395	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, .	6.6	26
396	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, .	4.0	40

#	ARTICLE	IF	CITATIONS
397	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, .	4.0	33
398	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, .	6.6	120
399	Evaluating combinations of diagnostic tests to discriminate different dementia types. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 509-518.	2.5	23
400	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , 2018, 104, 183-191.	2.9	25
401	Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1029-1039.	2.6	19
402	Subjective Cognitive Impairment Cohort (SCIENCE): study design and first results. <i>Alzheimer's Research and Therapy</i> , 2018, 10, .	6.6	112
403	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	17.6	132
404	Centenarian controls increase variant effect sizes by an average twofold in an extreme case-control analysis of Alzheimer's disease. <i>European Journal of Human Genetics</i> , 2018, 27, 244-253.	3.0	59
405	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 55, 521-537.	2.6	57
406	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2017, 55, 333-342.	2.6	21
407	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 687-697.	2.6	75
408	Screening for Mild Cognitive Impairment and Dementia with Automated, Anonymous Online and Telephone Cognitive Self-Tests. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 249-259.	2.6	23
409	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	2.5	62
410	Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations. <i>Neuropsychology Review</i> , 2017, 27, 245-257.	3.4	126
411	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 113-118.	6.3	136
412	Gait Speed and Grip Strength Reflect Cognitive Impairment and Are Modestly Related to Incident Cognitive Decline in Memory Clinic Patients With Subjective Cognitive Decline and Mild Cognitive Impairment: Findings From the 4C Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 846-854.	3.5	85
413	Quantification of Tau Load Using [18 F]AV1451 PET. <i>Molecular Imaging and Biology</i> , 2017, 19, 963-971.	2.2	46
414	CSF ApoE predicts clinical progression in nondemented APOE ϵ 4 carriers. <i>Neurobiology of Aging</i> , 2017, 57, 186-194.	3.4	27

#	ARTICLE	IF	CITATIONS
415	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. <i>Alzheimer's Research and Therapy</i> , 2017, 9, .	6.6	84
416	Effect of long-term storage in biobanks on cerebrospinal fluid biomarker A β 1-42, T τ , and P τ values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 45-50.	2.5	24
417	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE - E	2.6	38
418	The blood brain barrier in Alzheimer's disease. <i>Vascular Pharmacology</i> , 2017, 89, 12-18.	2.5	104
419	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. <i>NeuroImage: Clinical</i> , 2017, 15, 613-624.	3.3	44
420	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. <i>Human Brain Mapping</i> , 2017, 38, 4703-4715.	3.5	70
421	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 139-146.	2.5	22
422	Alzheimer's disease: The state of the art in resting-state magnetoencephalography. <i>Clinical Neurophysiology</i> , 2017, 128, 1426-1437.	1.3	94
423	Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy. <i>European Journal of Human Genetics</i> , 2017, 25, 973-981.	3.0	132
424	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	2.5	254
425	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , 2017, 140, 1466-1485.	8.4	166
426	Low normal cerebrospinal fluid A β 242 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , 2017, 81, 749-753.	6.6	24
427	The Pitfall of Behavioral Variant Frontotemporal Dementia Mimics Despite Multidisciplinary Application of the FTDC Criteria. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 959-975.	2.6	53
428	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017, 74, 1481.	17.6	88
429	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, .	3.4	58
430	[ICP130]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
431	[P1392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
432	Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 196-207.	2.5	76

#	ARTICLE	IF	CITATIONS
433	Directional information flow in patients with Alzheimer's disease. A source-space resting-state MEG study. <i>NeuroImage: Clinical</i> , 2017, 15, 673-681.	3.3	45
434	Lumbar puncture in patients with neurologic conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 108-110.	2.5	12
435	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 76-83.	2.5	46
436	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. <i>Neurobiology of Aging</i> , 2017, 57, 133-142.	3.4	137
437	Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, .	6.6	113
438	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	3.4	12
439	A novel CCM2 variant in a family with non-progressive cognitive complaints and cerebral microbleeds. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 220-226.	1.5	6
440	[P1â€“243]: ALPHAâ€“SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	2
441	[P1â€“009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEB-BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
442	[P2â€“473]: THE EFFECTS OF AMYLOID ON SEMANTIC COMPLEXITY IN SPONTANEOUS SPEECH IN SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
443	[P3â€“161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL AÎ² CLEARANCE?. <i>Alzheimer's and Dementia</i> , 2017, 13, 0.5	0.5	0
444	[P3â€“226]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
445	[P3â€“375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
446	[P3â€“386]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	1
447	[P3â€“407]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
448	[P3â€“422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
449	[P3â€“566]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
450	[P4â€“219]: [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0

#	ARTICLE	IF	CITATIONS
451	[P4â€“235]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, .	0.5	0
452	[ICâ€“Pâ€“005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€“ β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, .	0.5	1
453	[ICâ€“Pâ€“037]: SUBJECTIVE COGNITIVE DECLINE IS ASSOCIATED WITH ALTERED POSTERIOR CINGULATE CONNECTIVITY IN ELDERLY WITH A FAMILIAL HISTORY OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, .	0.5	1
454	[ICâ€“Pâ€“055]: EFFECT OF APOEâ€“ ϵ 2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, .	0.5	0
455	[ICâ€“Pâ€“085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, .	0.5	0
456	[ICâ€“Pâ€“095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, .	0.5	0
457	[ICâ€“Pâ€“106]: PREDICTING PROGRESSION IN PREâ€“DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, .	0.5	0
458	[ICâ€“Pâ€“110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, .	0.5	0
459	[ICâ€“Pâ€“203]: [18F]AV1451 BINDING POTENTIAL IN RELATION TO AMYLOID STATUS AND COGNITION IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, .	0.5	0
460	[ICâ€“Pâ€“206]: PARAMETRIC IMAGING OF TAU LOAD IN ALZHEIMER'S PATIENTS AND CONTROLS USING FLORTAUCIPIR. Alzheimer's and Dementia, 2017, 13, .	0.5	0
461	[TDâ€“Pâ€“020]: IMPROVING BRAIN HEALTH THROUGH AN ONLINE LIFESTYLE PROGRAM: PREFERENCES OF INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, .	0.5	0
462	[P1â€“250]: DECISION TREE ANALYSIS REVEALS TWO CUTâ€“OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, .	0.5	0
463	[P1â€“326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEBâ€“BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, .	0.5	0
464	[P1â€“375]: DATAâ€“DRIVEN DIAGNOSIS OF DEMENTIA DISORDERS: THE PREDICTND VALIDATION STUDY. Alzheimer's and Dementia, 2017, 13, .	0.5	2
465	[P1â€“440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, .	0.5	0
466	[P1â€“486]: OCCURRENCE AND PROFILE OF COGNITIVE IMPAIRMENT IN PATIENTS WITH HEART FAILURE, CAROTID OCCLUSIVE DISEASE AND VASCULAR COGNITIVE IMPAIRMENT: THE HEARTâ€“BRAIN CONNECTION STUDY. Alzheimer's and Dementia, 2017, 13, .	0.5	0
467	[P2â€“052]: THE DUTCH BRAIN HEALTH REGISTRY: OPTIMIZING RECRUITMENT FOR DEMENTIA RESEARCH. Alzheimer's and Dementia, 2017, 13, .	0.5	3
468	[P2â€“207]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOIDâ€“ β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS. Alzheimer's and Dementia, 2017, 13, .	0.5	0

#	ARTICLE	IF	CITATIONS
469	[P2â€“242]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
470	[P2â€“249]: CONTACTINâ€“1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NONâ€“DEMENTED CONTROLS. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
471	[P2â€“335]: EFFECT OF APOE Îµ2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
472	[F1â€“03â€“04]: BIOMARKERâ€“BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
473	[O1â€“01â€“02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
474	[O1â€“05â€“03]: CSF AMYLOID BETA 1â€“42 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSISâ€“DEPENDENT UPWARD DRIFT. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
475	[O1â€“05â€“04]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE: AN ASSAY COMPARISON STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
476	[O2â€“01â€“01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
477	[O2â€“10â€“06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
478	[O2â€“11â€“03]: PREDICTING PROGRESSION IN PREâ€“DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
479	[O2â€“12â€“03]: DURATION OF ALZHEIMER'S DISEASE IN THE PRECLINICAL, PRODROMAL AND DEMENTIA STAGE: A MULTIâ€“STATE MODEL ANALYSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	7
480	[O3â€“06â€“04]: PROMINENT NONâ€“MEMORY DEFICITS IN AD ARE ASSOCIATED WITH A FASTER DISEASE PROGRESSION. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
481	[P4â€“525]: DATAâ€“DRIVEN TAUâ€“PET COVARIANCE NETWORKS ENHANCE PREDICTION OF RETROSPECTIVE COGNITIVE CHANGE IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	1
482	[DTâ€“01â€“02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
483	[P3â€“075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. <i>Alzheimer's and Dementia</i> , 2017, 13, .	0.5	0
484	294Long-term prognosis of silent myocardial infarction detected by LGE-CMR in patients presenting with first acute myocardial infarction. <i>European Heart Journal</i> , 2017, 38, .	2.2	1
485	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, .	4.0	95
486	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017, 9, .	6.6	30

#	ARTICLE	IF	CITATIONS
487	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017, 9, .	6.6	54
488	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). <i>Clinical Biochemistry</i> , 2017, 50, 1061-1066.	1.8	18
489	Subjective Memory Complaints in APOE ε4 Carriers are Associated with High Amyloid-β Burden. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1115-1122.	2.6	51
490	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 261-270.	2.6	17
491	Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 927-943.	2.6	46
492	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 107-116.	2.6	5
493	Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer's Disease. An MEG Study with Virtual Electrodes. <i>Frontiers in Human Neuroscience</i> , 2016, 10, .	2.3	94
494	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. <i>Radiology</i> , 2016, 281, 865-875.	8.7	72
495	A profile of The Clinical Course of Cognition and Comorbidity in Mild Cognitive Impairment and Dementia Study (The 4C study): two complementary longitudinal, clinical cohorts in the Netherlands. <i>BMC Neurology</i> , 2016, 16, .	1.9	19
496	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 581-590.	2.6	43
497	P1-297: The Diagnostic Value of Amyloid Pet in an Unselected Cohort of Memory Clinic Patients. , 2016, 12, .		0
498	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 43-52.	2.5	52
499	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, .		0
500	P2-221: Cerebral Blood Flow Measured with Phase-Contrast MRI in AD, MCI and Controls. <i>Alzheimer's and Dementia</i> , 2016, 12, .	0.5	0
501	IC-P-196: Quantification of TAU Load Using [18F]AV-451 and PET. <i>Alzheimer's and Dementia</i> , 2016, 12, .	0.5	0
502	P4-179: MEG Cross-Frequency Analysis in Patients With Alzheimer's Disease. , 2016, 12, .		5
503	O3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. <i>Alzheimer's and Dementia</i> , 2016, 12, .	0.5	0
504	P1-178: Impact of Co-Morbid Amyloid Pathology on Clinical Phenotype of Patients with Vascular Cognitive Disorders. <i>Alzheimer's and Dementia</i> , 2016, 12, .	0.5	0

#	ARTICLE	IF	CITATIONS
505	ICâ€³â€³05: EEG Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimerâ€™s Disease And Controls. , 2016, 12, .		1
506	P1â€²84: Grey Matter Connectivity is Associated With Clinical Progression in Nonâ€Demented, Amyloid Positive Patients. Alzheimer's and Dementia, 2016, 12, .	0.5	0
507	P1â€²27: Crossâ€Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. , 2016, 12, .		0
508	ICâ€Pâ€¹097: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, .	0.5	0
509	ICâ€Pâ€¹103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€Demented Stages of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, .	0.5	0
510	ICâ€Pâ€¹106: Crossâ€Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, .	0.5	0
511	ICâ€Pâ€¹108: Cerebral Blood Flow Measured With Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, .	0.5	0
512	P2â€²48: Impact of Nonâ€Pharmacologic Interventions on Cognitive, Behavioral, and Emotional Functioning in Older Adults with Subjective Cognitive Decline: A Systematic Review of Controlled Trials. Alzheimer's and Dementia, 2016, 12, .	0.5	0
513	P2â€²82: EEGâ€Directed Connectivity from Posterior Brain Regions is Decreased in Dementia with Lewy Bodies: A Comparison with Alzheimer's Disease and Controls. Alzheimer's and Dementia, 2016, 12, .	0.5	0
514	ICâ€Pâ€¹147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, .	0.5	0
515	P3â€¹44: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, .	0.5	0
516	P4â€¹12: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Nonâ€Demented Elderly. Alzheimer's and Dementia, 2016, 12, .	0.5	0
517	P4â€¹53: Subjective Cognitive Decline and Progression to Dementia Due to AD and Nonâ€AD in Memory Clinic and Communityâ€Based Cohorts. Alzheimer's and Dementia, 2016, 12, .	0.5	1
518	P4â€¹91: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, .	0.5	0
519	P4â€²15: Quantification of Tau Load Using [18F]AVâ€¹451 and Pet. Alzheimer's and Dementia, 2016, 12, .	0.5	0
520	P4â€²24: Alzheimerâ€™s Disease Patients With Osas History Have Higher CSF Tau Levels. Alzheimer's and Dementia, 2016, 12, .	0.5	3
521	P4â€²40: Deciding About Diagnostic Testing for Alzheimerâ€™s Disease: Patientsâ€™ Views and Experiences. Alzheimer's and Dementia, 2016, 12, .	0.5	0
522	O1â€¹01â€¹01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, .		0

#	ARTICLE	IF	CITATIONS
523	O1â€05â€02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU. Alzheimer's and Dementia, 2016, 12, .	0.5	0
524	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, .	0.5	0
525	O4â€09â€04: Towards Dataâ€Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases. , 2016, 12, .		0
526	P1â€174: Costâ€Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach. Alzheimer's and Dementia, 2016, 12, .	0.5	0
527	Combinations of Service Use Types of People With Early Cognitive Disorders. Journal of the American Medical Directors Association, 2016, 17, 620-625.	2.4	10
528	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	3.3	182
529	Cerebrospinal Fluid Alzheimerâ€™s Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. Journal of Alzheimer's Disease, 2016, 54, 287-295.	2.6	105
530	Malnutrition and Risk of Structural Brain Changes Seen on Magnetic Resonance Imaging in Older Adults. Journal of the American Geriatrics Society, 2016, 64, 2457-2463.	2.9	38
531	P1â€418: Cliniciansâ€™ Views and Attitudes on Shared Decision Making in Diagnostic Testing for Alzheimerâ€™s Disease. , 2016, 12, .		0
532	P2â€335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples. Alzheimer's and Dementia, 2016, 12, .	0.5	0
533	P2â€342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. Alzheimer's and Dementia, 2016, 12, .	0.5	0
534	O5â€07â€02: Personalized Risk Estimates for MCI Patients: Taking Biomarkers Into the Clinic. , 2016, 12, .		1
535	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	3.4	50
536	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. Human Brain Mapping, 2016, 37, 978-988.	3.5	58
537	Cortical phase changes measured using 7â€T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. NMR in Biomedicine, 2016, 29, 1289-1294.	2.4	14
538	Suspected non-Alzheimer disease pathophysiology â€” concept and controversy. Nature Reviews Neurology, 2016, 12, 117-124.	28.6	276
539	The effect of physical activity on cognitive function in patients with dementia: A meta-analysis of randomized control trials. Ageing Research Reviews, 2016, 25, 13-23.	11.6	533
540	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology, 2016, 279, 838-848.	8.7	88

#	ARTICLE	IF	CITATIONS
541	Genome-wide analysis of genetic correlation in dementia with Lewy bodies, Parkinson's and Alzheimer's diseases. <i>Neurobiology of Aging</i> , 2016, 38, 214.e7-214.e10.	3.4	88
542	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 38, 21-31.	3.4	48
543	EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. <i>Neurobiology of Aging</i> , 2016, 41, 122-129.	3.4	57
544	Gray matter network disruptions and amyloid beta in cognitively normal adults. <i>Neurobiology of Aging</i> , 2016, 37, 154-160.	3.4	57
545	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 425-432.	6.3	113
546	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 235-243.	6.3	102
547	Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. <i>Molecular Psychiatry</i> , 2016, 22, 153-160.	7.8	116
548	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. <i>European Radiology</i> , 2016, 27, 1169-1175.	3.6	109
549	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.	8.4	69
550	O40504: A four-center study on the effect of polygenic risk score on cerebrospinal fluid markers and memory decline in mild cognitive impairment patients. , 2015, 11, .		0
551	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 505-512.	2.5	85
552	IC0203: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, .		0
553	Differential Expression of microRNA in Cerebrospinal Fluid as a Potential Novel Biomarker for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 243-252.	2.6	39
554	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S63-S86.	2.6	396
555	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 711-720.	2.6	86
556	Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1103-1110.	2.6	61
557	Serum Leptin is not Altered nor Related to Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 809-813.	2.6	50
558	More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 635-647.	2.6	52

#	ARTICLE	IF	CITATIONS
559	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 889-899.	2.6	13
560	O3â€9â€02: An eeg study into functional connectivity and hubs in Alzheimer's disease: What's going on in the posterior regions?. , 2015, 11, .		0
561	O4â€11â€04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, .		1
562	Loss of EEG Network Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies. <i>Movement Disorders</i> , 2015, 30, 1785-1793.	4.6	76
563	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Frontiers in Human Neuroscience</i> , 2015, 9, .	2.3	75
564	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 4421-4437.	3.5	227
565	O2â€02â€06: Slow gait speed and low grip strength are related to worse attention and mental speed in patients with subjective cognitive decline and mild cognitive impairment. , 2015, 11, .		0
566	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. <i>NeuroImage: Clinical</i> , 2015, 9, 418-429.	3.3	45
567	F2â€03â€03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, .		0
568	ICâ€01â€04: Diagnostic impact of [18F]flutemetamol amyloid imaging in youngâ€onset dementia. , 2015, 11, .		2
569	O1â€07â€02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. <i>Alzheimer's and Dementia</i> , 2015, 11, .	0.5	0
570	F2â€03â€02: Early onset APOEâ€4â€negative Alzheimer's disease patients show faster cognitive decline on nonâ€memory domains. , 2015, 11, .		1
571	F2â€03â€04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, .		2
572	O3â€14â€02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, .		0
573	O3â€14â€04: The relation between eeg spectral analysis and clinical progression in nonâ€demented, amyloidâ€positive subjects. <i>Alzheimer's and Dementia</i> , 2015, 11, .	0.5	1
574	F4â€02â€02: The influence of severity of total comorbidity on cognitive decline and conversion to dementia in memory clinic visitors. , 2015, 11, .		0
575	O5â€02â€03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression. , 2015, 11, .		0
576	O5â€05â€03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease. , 2015, 11, .		0

#	ARTICLE	IF	CITATIONS
577	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	3.4	27
578	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. <i>NeuroImage</i> , 2015, 111, 562-579.	4.4	316
579	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	8.4	349
580	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2340-2347.	3.4	62
581	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , 2015, 138, 2701-2715.	8.4	119
582	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <i>Brain</i> , 2015, 138, 2732-2749.	8.4	478
583	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. <i>European Radiology</i> , 2015, 25, 3050-3059.	3.6	94
584	The metabolic syndrome in a memory clinic population: Relation with clinical profile and prognosis. <i>Journal of the Neurological Sciences</i> , 2015, 351, 18-23.	2.1	24
585	Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. <i>European Neuropsychopharmacology</i> , 2015, 25, 1010-1017.	1.0	55
586	Angiotensin-Converting Enzyme in Cerebrospinal Fluid and Risk of Brain Atrophy. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 153-162.	2.6	18
587	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	16.6	1,474
588	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	16.6	609
589	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.0	132
590	The Rest-Activity Rhythm and Physical Activity in Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 45-49.	1.3	50
591	Microbleeds, Mortality, and Stroke in Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 539.	17.6	59
592	Standard biobanking conditions prevent evaporation of body fluid samples. <i>Clinica Chimica Acta</i> , 2015, 442, 141-145.	1.5	13
593	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , 2015, 7, .	6.6	128
594	Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study. <i>BMC Neurology</i> , 2015, 15, .	1.9	169

#	ARTICLE	IF	CITATIONS
595	Identifying bvFTD Within the Wide Spectrum of Late Onset Frontal Lobe Syndrome: A Clinical Approach. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1056-1066.	1.7	30
596	Prognostic Factors for Cognitive Decline After Intracerebral Hemorrhage. <i>Stroke</i> , 2015, 46, 2773-2778.	6.0	69
597	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 1275.	17.6	226
598	7T T2*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 20-26.	3.4	48
599	Disturbed phase relations in white matter hyperintensity based vascular dementia: An EEG directed connectivity study. <i>Clinical Neurophysiology</i> , 2015, 126, 497-504.	1.3	26
600	Cerebral perfusion in the predementia stages of Alzheimer's disease. <i>European Radiology</i> , 2015, 26, 506-514.	3.6	128
601	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e102995.	2.3	66
602	SUCLG2 identified as both a determinant of CSF A β 42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , 2014, 23, 6644-6658.	2.9	46
603	Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease. <i>Brain Connectivity</i> , 2014, 4, 337-346.	2.5	76
604	Mutation frequency of PRKAR1B and the major familial dementia genes in a Dutch early onset dementia cohort. <i>Journal of Neurology</i> , 2014, 261, 2085-2092.	3.4	16
605	The Added Value of 18-Fluorodeoxyglucose-Positron Emission Tomography in the Diagnosis of the Behavioral Variant of Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2014, 29, 607-613.	2.0	42
606	Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. <i>Human Molecular Genetics</i> , 2014, 23, 6139-6146.	2.9	211
607	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. <i>Neurology</i> , 2014, 82, 1768-1775.	1.0	55
608	Prevalence of cortical superficial siderosis in a memory clinic population. <i>Neurology</i> , 2014, 82, 698-704.	1.0	72
609	PLA β : PREDICTING CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE. , 2014, 10, .		0
610	Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging. <i>Radiology</i> , 2014, 270, 205-211.	8.7	76
611	Amyloid and its association with default network integrity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2014, 35, 779-791.	3.5	40
612	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2665-2670.	3.4	33

#	ARTICLE	IF	CITATIONS
613	O3â€œ06â€œ02: A REâ€œEVALUATION OF EARLY ALZHEIMER'S DISEASE BIOMARKERS ACCOUNTING FOR INACCURACY OF THE CLINICAL DIAGNOSIS. , 2014, 10, .		0
614	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, 2014, 71, 855.	17.6	151
615	Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement. Human Brain Mapping, 2014, 35, 1101-1110.	3.5	36
616	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, , .	5.5	7
617	Neurological abnormalities predict disability: the LADIS (Leukoaraiosis And DISability) study. Journal of Neurology, 2014, 261, 1160-1169.	3.4	17
618	The association of angiotensin-converting enzyme with biomarkers for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, .	6.6	72
619	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimerâ€™s disease correlates with pathology. Acta Neuropathologica Communications, 2014, 2, .	5.0	27
620	The Heart-Brain Connection: A Multidisciplinary Approach Targeting a Missing Link in the Pathophysiology of Vascular Cognitive Impairment. Journal of Alzheimer's Disease, 2014, 42, S443-S451.	2.6	50
621	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. Human Brain Mapping, 2014, 35, 2383-2393.	3.5	125
622	Comparison of Simplified Parametric Methods for Visual Interpretation of 11C-Pittsburgh Compound-B PET Images. Journal of Nuclear Medicine, 2014, 55, 1305-1307.	5.5	30
623	Distinct perfusion patterns in Alzheimerâ€™s disease, frontotemporal dementia and dementia with Lewy bodies. European Radiology, 2014, 24, 2326-2333.	3.6	56
624	The structure of the geriatric depressed brain and response to electroconvulsive therapy. Psychiatry Research - Neuroimaging, 2014, 222, 1-9.	1.8	26
625	Dysglycemia, brain volume and vascular lesions on MRI in a memory clinic population. Journal of Diabetes and Its Complications, 2014, 28, 85-90.	2.4	18
626	Actigraphic Motor Activity in Mild Cognitive Impairment Patients Carrying Out Short Functional Activity Tasks: Comparison between Mild Cognitive Impairment with and without Depressive Symptoms. Journal of Alzheimer's Disease, 2014, 40, 869-875.	2.6	19
627	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. Journal of Alzheimer's Disease, 2014, 41, 313-327.	2.6	354
628	Concordance Between Cerebrospinal Fluid Biomarkers and [11C]PIB PET in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2014, 41, 801-807.	2.6	116
629	The Influence of Co-Morbidity and Frailty on the Clinical Manifestation of Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 501-509.	2.6	38
630	P1â€œ258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION. , 2014, 10, .		1

#	ARTICLE	IF	CITATIONS
631	O2â€13â€05: APOLIPOPROTEIN Aâ€1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD. , 2014, 10, .		0
632	O5â€02â€02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, .		0
633	P1â€135: DIRECTED ANTERIORâ€TOâ€POSTERIOR COMMUNICATION IN THE BRAIN IS REVERSED IN DEMENTIA WITH LEWY BODIES AND IS RELATED TO ATTENTION DEFICITS. , 2014, 10, .		1
634	O2â€13â€03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, .		0
635	P1â€223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, .		0
636	ICâ€Pâ€009: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, .		0
637	ICâ€Pâ€085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, .		0
638	O4â€01â€05: CLINICALLY DIAGNOSED PROBABLE AD CASES WITH A NEGATIVE AMYLOID PET SCAN: CLINICAL FINDINGS. , 2014, 10, .		1
639	P1â€015: PROTEIN KINASE ACTIVITY DECREASES WITH BRAAK STAGE IN HIPPOCAMPAL POSTMORTEM BRAIN TISSUE AS REVEALED BY USING A PEPTIDEâ€BASED MICROARRAY PLATFORM. , 2014, 10, .		0
640	P1â€385: RATIONALE AND DESIGN OF THE NLâ€ENIGMA STUDY, A DUTCH 24â€WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE. , 2014, 10, .		0
641	O2â€07â€04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, .		0
642	ICâ€Pâ€077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, .		0
643	O4â€01â€06: NEURODEGENERATIVE AND COGNITIVE PROFILE OF PATIENTS WITH A TYPICAL PHENOTYPE OF AD BUT WITH A NEGATIVE AMYLOID SCAN. , 2014, 10, .		0
644	ICâ€Pâ€013: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, .		3
645	ICâ€Pâ€076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS. , 2014, 10, .		1
646	O2â€14â€03: THE RESTâ€ACTIVITY RHYTHM IS RELATED TO THE LEVEL OF PHYSICAL ACTIVITY IN EARLYâ€ONSET DEMENTIA. , 2014, 10, .		0
647	ICâ€Pâ€056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, .		0
648	ICâ€Pâ€109: RATIONALE AND DESIGN OF THE NLâ€ENIGMA STUDY: A DUTCH 24â€WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE. , 2014, 10, .		1

#	ARTICLE	IF	CITATIONS
649	P1â€¹134: LOSS OF NETWORK INTEGRATION IS RELATED TO COGNITIVE IMPAIRMENT IN DEMENTIA WITH LEWY BODIES. , 2014, 10, .		0
650	P1â€¹149: CSF VILIPâ€¹1 AND YKLâ€¹40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE. , 2014, 10, .		0
651	P4â€¹273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, .		0
652	O1â€¹02â€¹04: 7T T2*â€¹WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLYâ€¹AND LATEâ€¹ONSET AD. , 2014, 10, .		0
653	O4â€¹01â€¹01: DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA. , 2014, 10, .		1
654	P3â€¹096: MAGNETOENCEPHALOGRAPHY IN DEMENTIA: THE STATE OF THE ART. , 2014, 10, .		1
655	P1â€¹174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME. , 2014, 10, .		0
656	P1â€¹415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, .		0
657	Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. Acta Neuropathologica Communications, 2014, 2, 79.	5.0	18
658	Alzheimer's disease patients not carrying the apolipoprotein E ϵ 4 allele show more severe slowing of oscillatory brain activity. Neurobiology of Aging, 2013, 34, 2158-2163.	3.4	24
659	Frontotemporale dementie en de psychiatrische differentiaaldiagnose: twee gevalsbeschrijvingen en de rationale van de "Laat Ontstaan Frontaal syndroom (LOF)-studie"™. Tijdschrift Voor Neuropsychiatrie En Gedragsneurologie, 2013, 1, 72-79.	0.0	0
660	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiology of Aging, 2013, 34, 128-136.	3.4	158
661	S1â€¹02â€¹02: Clinical and neuropsychological features as predictors from MCI to Alzheimer'sâ€¹type dementia. , 2013, 9, .		0
662	O3â€¹05â€¹01: Physical activity, independent functioning and emotional wellâ€¹being in earlyâ€¹onset dementia. , 2013, 9, .		0
663	Different patterns of gray matter atrophy in early- and late-onset Alzheimer'sâ€¹disease. Neurobiology of Aging, 2013, 34, 2014-2022.	3.4	183
664	O1â€¹09â€¹01: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting. , 2013, 9, .		0
665	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2488-2494.	3.4	72
666	F5â€¹01â€¹02: CSF biomarkers and APOE genotype as predictors of clinical progression in patients with subjective complaints. , 2013, 9, .		1

#	ARTICLE	IF	CITATIONS
667	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. <i>Neurology</i> , 2013, 80, 1124-1132.	1.0	126
668	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. <i>Neurobiology of Aging</i> , 2013, 34, 2023-2036.	3.4	404
669	Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. <i>Radiology</i> , 2013, 267, 221-230.	8.7	239
670	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. <i>Neurology</i> , 2013, 80, 359-365.	1.0	111
671	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013, 80, 1048-1056.	1.0	176
672	Preclinical AD predicts decline in memory and executive functions in subjective complaints. <i>Neurology</i> , 2013, 81, 1409-1416.	1.0	134
673	Cerebral atrophy in elderly with subjective memory complaints. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 38, 358-364.	3.4	9
674	Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 169-178.	2.6	22
675	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 79-85.	2.6	21
676	Progression to dementia in memory clinic patients without dementia. <i>Neurology</i> , 2013, 81, 1342-1349.	1.0	24
677	Increase in Cerebrospinal Fluid F2-Isoprostanes is Related to Cognitive Decline in APOE ϵ 4 Carriers. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 563-570.	2.6	21
678	Single-Subject Grey Matter Graphs in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e58921.	2.3	119
679	Integrative EEG biomarkers predict progression to Alzheimer's disease at the MCI stage. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, .	4.0	182
680	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. <i>European Radiology</i> , 2013, 24, 397-404.	3.6	31
681	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , 2012, 79, 1809-1816.	1.0	136
682	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. <i>Neurology</i> , 2012, 78, 47-54.	1.0	286
683	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. <i>Brain</i> , 2012, 135, 2115-2125.	8.4	116
684	Early Onset Alzheimer's Disease is Associated with a Distinct Neuropsychological Profile. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 101-108.	2.6	168

#	ARTICLE	IF	CITATIONS
685	Bloodâ€‘brain barrier P-glycoprotein function in Alzheimer's disease. <i>Brain</i> , 2012, 135, 181-189.	8.4	284
686	White Matter Lesion Progression in LADIS. <i>Stroke</i> , 2012, 43, 2643-2647.	6.0	96
687	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 319-327.	2.6	77
688	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012, 78, 468-476.	1.0	159
689	Microbleeds in vascular dementia: Clinical aspects. <i>Experimental Gerontology</i> , 2012, 47, 853-857.	3.7	50
690	S2â€‘02â€‘01: Understanding (endo)phenotypical heterogeneity: The role of age and APOE. <i>Alzheimer's and Dementia</i> , 2012, 8, .	0.5	0
691	O4â€‘03â€‘01: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2012, 8, .	0.5	0
692	Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, .	2.3	25
693	Microglial activation in healthy aging. <i>Neurobiology of Aging</i> , 2012, 33, 1067-1072.	3.4	141
694	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , 2012, 33, 1591-1598.	3.4	58
695	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2018-2028.	3.4	375
696	Young Alzheimer patients show distinct regional changes of oscillatory brain dynamics. <i>Neurobiology of Aging</i> , 2012, 33, 1008.e25-1008.e31.	3.4	37
697	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e1-1011.e9.	3.4	57
698	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012, 33, 2272-2281.	3.4	78
699	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2012, 79, 763-769.	1.0	74
700	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1145-1148.	6.3	28
701	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. <i>BMC Neuroscience</i> , 2012, 13, .	2.1	27
702	Disruption of Functional Brain Networks in Alzheimer's Disease: What Can We Learn from Graph Spectral Analysis of Resting-State Magnetoencephalography?. <i>Brain Connectivity</i> , 2012, 2, 45-55.	2.5	93

#	ARTICLE	IF	CITATIONS
703	Disrupted modular brain dynamics reflect cognitive dysfunction in Alzheimer's disease. <i>NeuroImage</i> , 2012, 59, 3085-3093.	4.4	218
704	Clinical aspects of microbleeds in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2012, 322, 56-58.	2.1	20
705	Brain atrophy accelerates cognitive decline in cerebral small vessel disease. <i>Neurology</i> , 2012, 78, 1785-1792.	1.0	136
706	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 990-1000.	5.5	151
707	Cerebral white matter changes are associated with abnormalities on neurological examination in non-disabled elderly: the LADIS study. <i>Journal of Neurology</i> , 2012, 260, 1014-1021.	3.4	36
708	Brain microbleeds and Alzheimer's disease: innocent observation or key player?. <i>Brain</i> , 2011, 134, 335-344.	8.4	311
709	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 126-135.	6.3	695
710	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. <i>Journal of the Neurological Sciences</i> , 2011, 307, 100-105.	2.1	62
711	Progression from MCI to AD: Predictive value of CSF A β 42 is modified by APOE genotype. <i>Neurobiology of Aging</i> , 2011, 32, 1372-1378.	3.4	13
712	Early-onset versus late-onset Alzheimer's disease: A role for APOE e4?. , 2011, 7, .		0
713	Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1073-1079.	2.6	22
714	Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ϵ 4 allele. <i>Lancet Neurology</i> , The, 2011, 10, 280-288.	17.9	295
715	Visual assessment of posterior atrophy development of a MRI rating scale. <i>European Radiology</i> , 2011, 21, 2618-2625.	3.6	372
716	Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. <i>Stroke</i> , 2011, 42, 1894-1900.	6.0	129
717	Incident lacunes influence cognitive decline. <i>Neurology</i> , 2011, 76, 1872-1878.	1.0	199
718	Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 353-366.	2.3	152
719	EEG abnormalities in early and late onset Alzheimer's disease: understanding heterogeneity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 67-71.	6.3	47
720	Joint Effect of Hypertension and APOE Genotype on CSF Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1083-1090.	2.6	35

#	ARTICLE	IF	CITATIONS
721	Translational Research in Genomics of Alzheimer's Disease: A Review of Current Practice and Future Perspectives. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 967-980.	2.6	17
722	Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 242-247.	1.3	21
723	Amyloid- β (1-42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease. <i>Clinical Chemistry</i> , 2010, 56, 248-253.	1.1	332
724	Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study. <i>Stroke</i> , 2010, 41, .	6.0	86
725	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 547-551.	6.3	112
726	Additional Value of CSF Amyloid- β 40 Levels in the Differentiation between FTLD and Control Subjects. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 445-452.	2.6	39
727	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. <i>Neurobiology of Aging</i> , 2010, 31, 758-764.	3.4	96
728	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 882-884.	6.3	57
729	Early-Versus Late-Onset Alzheimer's Disease: More than Age Alone. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 1401-1408.	2.6	416
730	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 253-260.	2.6	82
731	CSF β -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 87-95.	2.6	87
732	CSF Biomarkers in Alzheimer's Disease and Controls: Associations with APOE Genotype are Modified by Age. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 601-607.	2.6	47
733	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 478-483.	6.3	108
734	Relationship of Cerebrospinal Fluid Markers to 11 C-PiB and 18 F-FDDNP Binding. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1464-1470.	5.5	163
735	Detection of Alzheimer Pathology In Vivo Using Both 11 C-PIB and 18 F-FDDNP PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 191-197.	5.5	122
736	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64- β -Detector Row CT. <i>Radiology</i> , 2009, 253, 174-183.	8.7	133
737	MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. <i>Stroke</i> , 2009, 40, 492-498.	6.0	127
738	CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. <i>Neurology</i> , 2009, 72, 1056-1061.	1.0	103

#	ARTICLE	IF	CITATIONS
739	A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. <i>Annals of Clinical Biochemistry</i> , 2009, 46, 235-240.	1.7	161
740	CSF biomarkers predict rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2009, 73, 1353-1358.	1.0	139
741	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. <i>Neurology</i> , 2009, 73, 935-940.	1.0	75
742	Differential association of [11C]PIB and [18F]FDNP binding with cognitive impairment. <i>Neurology</i> , 2009, 73, 2079-2085.	1.0	45
743	Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. <i>BMC Neuroscience</i> , 2009, 10, .	2.1	354
744	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the Tj ETQq0 00rgBT /Overlock 10		
745	Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data. <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 353-355.	3.1	6
746	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. <i>European Radiology</i> , 2009, 19, 2826-2833.	3.6	95
747	Patients With Alzheimer Disease With Multiple Microbleeds. <i>Stroke</i> , 2009, 40, 3455-3460.	6.0	207
748	Progression of Mild Cognitive Impairment to Dementia. <i>Stroke</i> , 2009, 40, 1269-1274.	6.0	134
749	CSF biomarker levels in early and late onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2009, 30, 1895-1901.	3.4	130
750	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	16.6	1,052
751	Small vessel versus large vessel vascular dementia. <i>Journal of Neurology</i> , 2008, 255, 1644-1651.	3.4	57
752	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 387-392.	2.2	37
753	De diagnostische waarde van de Visuele Associatie Test (vat) in een geheugenpoliklinieksetting. <i>Neuropraxis</i> , 2008, 12, 3-8.	0.0	0
754	Transcranial Doppler Blood Flow Assessment in Patients With Mild Heart Failure: Correlates With Neuroimaging and Cognitive Performance. <i>Congestive Heart Failure</i> , 2008, 14, 61-65.	2.3	43
755	Global dynamical analysis of the EEG in Alzheimer's disease: Frequency-specific changes of functional interactions. <i>Clinical Neurophysiology</i> , 2008, 119, 837-841.	1.3	99
756	Investigation of resting-state EEG functional connectivity in frontotemporal lobar degeneration. <i>Clinical Neurophysiology</i> , 2008, 119, 1732-1738.	1.3	55

#	ARTICLE	IF	CITATIONS
757	EEG functional connectivity and ApoE genotype in Alzheimer's disease and controls. <i>Clinical Neurophysiology</i> , 2008, 119, 2727-2732.	1.3	28
758	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. <i>Current Medical Research and Opinion</i> , 2008, 24, 2561-2574.	2.1	131
759	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 669-675.	3.4	104
760	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. <i>Brain</i> , 2008, 131, 3286-3298.	8.4	276
761	Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, .	2.3	16
762	The use of EEG in the diagnosis of dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 377-380.	6.3	84
763	Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia. <i>Stroke</i> , 2008, 39, 317-322.	6.0	82
764	Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period. <i>Stroke</i> , 2008, 39, 1414-1420.	6.0	357
765	Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities. <i>American Journal of Neuroradiology</i> , 2008, 29, 1296-1301.	2.6	75
766	Whole-brain atrophy rate in Alzheimer disease. <i>Neurology</i> , 2008, 70, 1836-1841.	1.0	107
767	On the Etiology of Incident Brain Lacunes. <i>Stroke</i> , 2008, 39, 3083-3085.	6.0	83
768	Brain magnetic resonance imaging abnormalities in patients with heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1003-1009.	7.4	144
769	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. <i>Neurology</i> , 2007, 69, 1491-1497.	1.0	81
770	The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia. <i>Stroke</i> , 2007, 38, 3182-3185.	6.0	118
771	Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1023.	6.8	74
772	Lobar Distribution of Changes in Gray Matter and White Matter in Memory Clinic Patients: Detected Using Magnetization Transfer Imaging. <i>American Journal of Neuroradiology</i> , 2007, 28, 1938-1942.	2.6	20
773	Longitudinal changes of CSF biomarkers in memory clinic patients. <i>Neurology</i> , 2007, 69, 1006-1011.	1.0	117
774	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2007, 28, 1070-1074.	3.4	165

#	ARTICLE	IF	CITATIONS
775	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. <i>Diabetic Medicine</i> , 2007, 24, 166-171.	2.9	89
776	ASSOCIATION BETWEEN VITAMIN B 6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 956-958.	2.9	10
777	Profile of Cognitive Impairment in Chronic Heart Failure. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1764-1770.	2.9	176
778	Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 215-224.	4.0	28
779	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. <i>Neuroradiology</i> , 2007, 49, 967-976.	2.1	282
780	White Matter Hyperintensities Rather Than Lacunar Infarcts Are Associated With Depressive Symptoms in Older People: The LADIS Study. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 834-841.	1.7	143
781	Magnetization transfer imaging of gray and white matter in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1757-1762.	3.4	30
782	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. <i>Journal of Neurology</i> , 2006, 253, 1189-1196.	3.4	111
783	Infratentorial Abnormalities in Vascular Dementia. <i>Stroke</i> , 2006, 37, 105-110.	6.0	32
784	Prevalence and severity of microbleeds in a memory clinic setting. <i>Neurology</i> , 2006, 66, 1356-1360.	1.0	282
785	Hippocampal atrophy in Alzheimer disease: Age matters. <i>Neurology</i> , 2006, 66, 236-238.	1.0	142
786	Usefulness of Longitudinal Measurements of β -Amyloid $_{1-42}$ in Cerebrospinal Fluid of Patients with Various Cognitive and Neurologic Disorders. <i>Clinical Chemistry</i> , 2006, 52, 1604-1606.	1.1	16
787	The effect of APOE genotype on clinical phenotype in Alzheimer disease. <i>Neurology</i> , 2006, 67, 526-527.	1.0	92
788	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 439-442.	6.3	182
789	Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. <i>Archives of Neurology</i> , 2006, 63, 144.	6.8	14
790	MRI measures and progression of cognitive decline in nondemented elderly attending a memory clinic. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 1060-1066.	2.2	34
791	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1497-1500.	6.3	108
792	Epidemiology and risk factors of dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, v2-v7.	6.3	460

#	ARTICLE	IF	CITATIONS
793	Use of laboratory and imaging investigations in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, v45-v52.	6.3	12
794	Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. <i>Stroke</i> , 2005, 36, 2116-2120.	6.0	330
795	Memory complaints in patients with normal cognition are associated with smaller hippocampal volumes. <i>Journal of Neurology</i> , 2004, 251, .	3.4	161
796	Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. <i>Neurology</i> , 2003, 60, 1558-1559.	1.0	7
797	Cognitive decline in AD and mild cognitive impairment is associated with global brain damage. <i>Neurology</i> , 2002, 59, 874-879.	1.0	67
798	Magnetization transfer imaging in normal aging, mild cognitive impairment, and Alzheimer's disease. <i>Annals of Neurology</i> , 2002, 52, 62-67.	6.6	127
799	Frontal lobe damage and thalamic volume changes. <i>NeuroReport</i> , 2000, 11, 3039-3041.	1.5	7
800	Title is missing!. , 0, .		2
801	Quantitation of PET spatial extent as a potential adjunct to visual interpretation of [18F]florotau imaging: TAU-SPEX. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, 52, 5135-5149.	5.5	0
802	CSF proteomic profiles related to cognitive decline in MCI A+ depend on tau levels. <i>Brain</i> , 0, 148, 4389-4399.	8.4	0
803	Connectivity as a universal predictor of tau progression in atypical Alzheimer's disease. <i>Brain</i> , 0, 148, 3893-3912.	8.4	4
804	Cognitive and physical activities are associated with cognitive resilience in a memory clinic cohort. <i>Brain Communications</i> , 0, 7, .	3.6	0
805	The association between the MIND-NL diet, Dutch dietary guidelines, and global cognitive function in an older population at risk for cognitive decline. <i>Journal of Nutrition, Health and Aging</i> , 0, 29, 100680.	3.1	0
806	Genetic testing of common and rare variants in dementia patients from a memory clinic. <i>Alzheimer's Research and Therapy</i> , 0, 17, .	6.6	0
807	General practitioners' perspectives on blood biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 0, 17, .	2.5	0
808	Opposing views or like-minded? International working group and Alzheimer's association criteria. <i>Brain</i> , 0, , .	8.4	0
809	Integrative analysis of cerebrospinal fluid biomarkers, metabolomics, and polygenic risk reveals novel metabolite associations with Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 0, 108, 1677-1695.	2.6	0
810	Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 0, 20, .	14.1	0

#	ARTICLE	IF	CITATIONS
811	The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts. <i>Alzheimer's and Dementia</i> , 0, 21, .	0.5	0
812	Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline. <i>JAMA Network Open</i> , 0, 8, e2545862.	6.6	0
813	Towards a Dutch nationwide registry for Alzheimer's disease and other dementia's: rationale, design, and initial observations of the ABOARD Cohort. <i>Alzheimer's and Dementia</i> , 0, 21, .	0.5	0
814	â€œRealâ€worldâ€™ eligibility for antiâ€amyloid treatment in a tertiary memory clinic setting. <i>Alzheimer's and Dementia</i> , 0, 21, .	0.5	0
815	Education, socioeconomic status, modifiable dementia risk and cognitive performance in older adults at risk of cognitive decline: a crossâ€sectional study of the FINGERâ€NL trial. <i>Alzheimer's and Dementia</i> , 0, 21, .	0.5	0
816	Women are less likely to be eligible for AD trials than men.. <i>Alzheimer's and Dementia</i> , 0, 21, .	0.5	0
817	Cognitive and neuroimaging trajectories in the behavioral variant of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 0, 21, .	0.5	0
818	Cerebrospinal fluid proteome alterations related to depressive symptoms in cognitive decline and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 0, 21, .	0.5	0
819	Distinct CSF lipidomic profiles are associated with five proteomic subtypes in patients with Alzheimerâ€™s disease. , 0, 2, .		0